The size of the Checkpoint Inhibitors Market in Latin America was valued at USD 1.81 million in 2022. It is further expected to reach USD 6.51 billion by 2027, growing at a CAGR of 29.2 % during the forecast period.
Checkpoint inhibitors are cancer medicines that target the checkpoints. As a result, the market for checkpoint inhibitors is expected to grow as cancer incidence rates rise.
The checkpoint inhibitors market in Latin American is estimated to be driven by the sharp rise in various types of malignancies, as well as a sharp rise in the geriatric population in Latin America, particularly in industrialized and rising economies. In addition, during the forecast period, the increase in the number of cancer cases in Latin America is expected to contribute to the growth of the checkpoint inhibitors market. Lung, prostate, bowel, and female breast cancer are the four most frequent kinds of cancer, accounting for 43 percent of all new cancer cases.
Increased cancer prevalence in Latin America, high demand for ideal therapeutics for cancer treatment, favorable reimbursement policies offered by manufacturers and insurance providers in some countries, and increased awareness of checkpoint inhibitors for cancer treatment due to positive results are the main factors driving the growth of the Latin American checkpoint inhibitors market.
However, the Latin American checkpoint inhibitor market is projected to be hampered by the high cost of cancer therapy using checkpoint inhibitors. There is a lot of pressure to keep expenses down and show value. Political uncertainty and ongoing economic stress are putting public health care funding in jeopardy in several countries. The lack of cost-effective cancer medicines has influenced the population's health and resulted in poor life expectancy. A course of intravenous checkpoint inhibitor medication, for example, costs between $150,000 and $250,000, which is too expensive, especially in nations without public health care. As a result of the high cost of checkpoint inhibitor cancer treatment, the checkpoint inhibitor market is projected to be limited.
This research report on the Latin America checkpoint inhibitors market has been segmented and sub-segmented into the following categories.
By Drug:
By Application:
By Country:
Latin America is predicted to have a moderate share of the global checkpoint inhibitors market during the forecast period. Mexico and Brazil have the largest market share in Latin America. During the forecast period, the presence of a large population of baby boomers in Mexico necessitated the efficient treatment of various chronic diseases such as diabetes, skin cancer, urothelial carcinomas, and lung cancers, as well as the growing prevalence of various chronic diseases such as diabetes, skin cancer, urothelial carcinomas, and lung cancers.
KEY MARKET PLAYERS:
Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, and others play an influential role in the Latin America checkpoint inhibitors market Novartis International AG, and Kite Pharma.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Type
5.1.1 Introduction
5.1.2 PD-1 inhibitors
5.1.3 PD-L1 inhibitors
5.1.4 CTLA-4
5.1.5 Chimeric Antigen Receptor T-cell
5.1.6 Others
5.1.7 Y-o-Y Growth Analysis, By Drug Type
5.1.8 Market Attractiveness Analysis, By Drug Type
5.1.9 Market Share Analysis, By Drug Type
5.2 Application
5.2.1 Introduction
5.2.2 Lung cancer
5.2.3 Renal cancer
5.2.4 Blood cancer
5.2.5 Bladder Cancer
5.2.6 Hodgkin lymphoma
5.2.7 Melanoma
5.2.8 Others
5.2.9 Y-o-Y Growth Analysis, By Application
5.2.10 Market Attractiveness Analysis, By Application
5.2.11 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Drug Type
6.1.3.3 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Drug Type
6.1.4.3 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Drug Type
6.1.5.3 By Application
6.2 Brazil
6.3 Mexico
6.4 Rest of Latin America
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Merck & Co., Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Bristol-Myers Squibb
8.3 Roche
8.4 AstraZeneca
8.5 Ono Pharmaceutical Co., Ltd.
8.6 Juno Therapeutics
8.7 Novartis International AG
8.8 Kite Pharma
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
